You are about to leave jnjmedtech.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
Advanced robotics enable successful lung biopsies
Together we completed over 20,000 cases.1 When using MONARCH™, physicians achieved over 15% improvement in overall diagnostic yield2 compared to traditional bronchoscopy. This means fewer patients had to ‘wait and see.’
average number of biopsies a patient needs to get diagnosis3
5-year survival rate if lung cancer has spread to regional lymph nodes4
survival rate if lung cancer is diagnosed and treated early5
You are entering a rotating card carousel. Navigate the items by using the previous/next buttons.
Multicenter Study 2023 : Diagnostic Outcomes of Robotic-Assisted Bronchoscopy for Pulmonary Lesions in a Real-World Multicenter Community
The largest retrospective multicenter study (as of 05/23) evaluating the diagnostic yield in patients undergoing RAB for the diagnosis of pulmonary lesions. Use of the MONARCH™ Platform led to high diagnostic yield, despite a high proportion of traditionally challenging lesions
CHEST 2023 Poster: Safety Results From Multicenter Observational Real-World Robotic Bronchoscopy (TARGET) Study
Learn how clinicians were able to reach small and peripheral nodules and biopsy them with a safety profile comparable with non-robotic bronchoscopy. Pneumothorax rates were 4.7% and bleeding events were 2.6%.
AABIP 2022 Poster: Demographic and Lesion Characteristics of first 443 subjects in TARGET.
Learn about the interim analysis of a large multicenter prospective real-world observation study. RAB with MONARCH™ Platform had 97.5% navigation success with median lesion size reported as 18.5 mm. Compared to a prior prospective study of the MONARCH™ Platform, nodule size appears smaller and procedure time is shorter in this cohort.7
Journal of Bronchology & Interventional Pulmonology 2022 - Robotic-assisted Bronchoscopy and Cone-beam CT (CBCT). A Retrospective Series.
Learn from a physician’s recent experience in the use of CBCT with the MONARCH™ Platform, where 100% tool-in-lesion confirmation was achieved.6
CHEST 2022 Presentation: Combining Real-time 3D Imaging and Augmented Fluoroscopy with Robotic Bronchoscopy for the Diagnosis of Peripheral Lung Nodules.
Read about results from the largest cohort to date on combining the use of the Monarch™ Platform and Body Vision technologies. The data is a retrospective review of 45 patients who underwent navigational bronchoscopy with biopsy using both platforms. 91% diagnostic yield was achieved at 1-year follow-up.
Gateway Customer Portal
Our customers have access to data and insights through our secure web-portal to support their MONARCH™ experience. Improve efficiency with access to platform usage data, order information, training, and marketing support materials.